Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Brown Vows Floor Fight On Follow-on Biologics

This article was originally published in The Pink Sheet Daily

Executive Summary

But he'll need to find a length of brand exclusivity that attracts enough senators while continuing to satisfy generic firms and their allies.

You may also be interested in...



Teva Launching "6 vs 12" Campaign On Follow-On Biologics

Six-video series will profile patients struggling to pay for biologics in effort to make the case for brand exclusivity shorter than 12 years.

Teva Launching "6 vs 12" Campaign On Follow-On Biologics

Six-video series will profile patients struggling to pay for biologics in effort to make the case for brand exclusivity shorter than 12 years.

And Then There Were 12: Follow-on Biologics Picture Coming Into Focus

It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel